Andrew McMillan
Nottingham University Hospitals NHS Trust
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andrew McMillan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:21 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT01679119 · Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing ChemotherapyUniversity College, London · completed · Diffuse Large B Cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:21 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:21 UTC. The ranking covers the 200 most relevant of 83 PubMed records, and a shared surname and initials can bring in a namesake. All 83 on PubMed
- 899 citationsRCR 23.2
- Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.Blood · 2007692 citationsRCR 13.9
- 678 citationsRCR 30.5
- Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.J Clin Oncol · 2020655 citationsRCR 30.2
- 610 citationsRCR 13.6
- 562 citationsRCR 17.9
- Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial.Int J Radiat Oncol Biol Phys · 2006541 citationsRCR 17.0
- 454 citationsRCR 12.5
- 313 citationsRCR 6.4
- 308 citationsRCR 9.5